Search

In the MESKO clinical trial, treatment with low-dose methotrexate did not improve pain or joint inflammation in individuals with inflammatory knee osteoarthritis.

The results of a new clinical trial suggest that methotrexate could be an alternative to prednisone as first-line treatment for pulmonary sarcoidosis.

In the phase III SELECT-GCA trial, upadacitinib at a dose of 15 mg daily was superior to placebo with respect to achievement of sustained remission of giant cell arteritis at 52 weeks.

Altered metabolism of the tricarboxylic acid cycle metabolite fumarate drives activation of interferon release in systemic sclerosis monocytes, suggesting a potential therapeutic approach.

Analysis of synovial tissue samples led to the identification of inflammatory and fibrotic subgroups of osteoarthritis, which were associated with distinct fibroblast and macrophage populations.

Cumulative exposure to oestrogens over a woman’s lifetime is associated with the risk of developing seronegative inflammatory arthritis.

In a phase III trial, the addition of obinutuzumab to standard therapy for lupus nephritis led to an increase in the proportion of patients with a complete renal response.

Research demonstrates that the SARS-CoV-2 protein ORF8 drives osteoclastogenesis, establishing a direct link between viral infection and bone loss.

In a phase III clinical trial of abatacept for idiopathic inflammatory myopathy, the primary endpoint was not met but the results suggest abatacept could have benefits in some subtypes of the disease.

In a new study, inhibition of CDK7 disrupted the RNA polymerase II transcription cycle, leading to anti-inflammatory effects and metabolic reprogramming in macrophages and attenuation of arthritis in mouse models.

In a phase III trial, the CD19-targeting antibody inebilizumab was effective for the treatment of IgG4-related disease over 52 weeks.

New research suggests that insulin-like growth factor 1 is an important contributor to Wnt-induced joint damage, and that its suppression could represent a promising therapeutic strategy for osteoarthritis.

In an open-label clinical trial, collagenase injection was not noninferior to limited fasciectomy for the treatment of Dupuytren contracture.

Findings from an observational study suggest that the frequency of uveitis in patients with spondyloarthritis has declined since the introduction of biologic DMARDs.

The bispecific T cell engager antibody teclistamab has now been used to successfully treat five patients with treatment-resistant autoimmune rheumatic diseases.

Consistent with findings from clinical trials, in a retrospective cohort study, Janus kinase inhibitors improved pain associated with rheumatoid arthritis as well as or better than biologic DMARDs in clinical practice.

Results of a new study indicate that eosinophils have a role in maintaining bone homeostasis through their inhibitory effects on bone-resorbing osteoclasts.

Treatment with the endogenous metabolite itaconate induced phenotypic and metabolic changes in fibroblast-like synoviocytes and reduced the severity of arthritis in an animal model.

New research provides a potential explanation for why long-term sclerostin neutralization leads to continued bone mass gain, despite attenuation of its short-term effects on bone formation.

Drugs used to treat osteoporosis could slow the progression of osteoarthritis, according to the findings of a study in mice.

In a head-to-head phase III trial of two drugs that target IL-5 or its receptor, benralizumab was noninferior to mepolizumab for the induction of remission in patients with eosinophilic granulomatosis with polyangiitis.

New findings suggest that inhibition of macrophage fumarate hydratase leads to the release of mitochondrial RNA, which in turn mediates type I interferon production.

In patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis in sustained remission, reinfusion with rituximab after B cell repopulation resulted in fewer clinical relapses than did reinfusion following serological ANCA flare.

A meta-analysis of data from six genome-wide association study cohorts implicates several signalling pathways, including Hedgehog and Notch signalling, in Dupuytren disease.

New research suggests that the transcription factor ETS1 expressed in fibroblasts regulates the tissue-destructive properties of these cells in multiple diseases, and could offer a novel therapeutic strategy.

In an observational study, SARS-CoV-2 antibody therapy used as pre-exposure prophylaxis reduced the incidence of COVID-19 in individuals with rheumatic diseases.

New findings support the use of targeted next-generation sequencing of NOD2 to reassess the diagnosis of juvenile idiopathic arthritis in patients with signs and symptoms suggestive of Blau syndrome.

New research shows that a recombinant antibody that binds type II collagen protects against the development of arthritis in mice by blocking neutrophil recruitment.

Using multi-omics analyses, researchers have identified two distinct immunological phenotypes of microscopic polyangiitis, which could inform prognosis and personalized treatment.

New research shows that deficiency of the sulfation-related SLC26A2 affects osteocyte formation, and that targeting downstream mediators can ameliorate SLC26A2-deficient osteoporosis.

New research shows that the amino acid l-arginine ameliorates arthritis and inhibits inflammatory bone loss by altering energy metabolism in osteoclasts.

New research shows that PD1 can be potentiated by freeing up its ligand, PDL1, from binding to CD80, thereby improving symptoms of autoimmune disease in animal models.